Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

657380

registered interest
date	12/12/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	IVF
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government, further to the Written Answers by Lord Prior of Brampton on 17 October (HL2340) and 5 December (HL3452), whether any members of the expert panel convened by the Human Fertilisation and Embryology Authority (HFEA) shared private and confidential correspondence with members of the HFEA Executive that had not been submitted to the Authority as part of any formal calls for evidence; and if so, what were the particular circumstances that necessitated giving weight to any material not intended for publication.
tabling member printed	Lord Alton of Liverpool
uin	HL4014
answer	answer is ministerial correction date of answer 20/12/2016 answer text <p>The Human Fertilisation and Embryology Authority (HFEA) has advised that the Expert Panel has met on four occasions over the past four years. On each occasion a formal call for evidence was issued. With regard to the most recent report, the Panel received confidential correspondence on particular issues. Panel members were able to share private correspondence with the Secretariat that supports the Panel, where relevant. Where any evidence has influenced the reports it has been cited.</p><p>The HFEA has also advised that it approached John Zhang, following the publication of the abstract from the October 2016 American Society for Reproductive Medicine meeting, entitled “First live birth using human oocytes reconstituted by spindle nuclear transfer for mitochondrial DNA mutation causing Leigh syndrome”. A copy of the abstract is attached. The Panel also interviewed Prof. Zhang to further understand the methods used. The Panel’s report references the Zhang work.</p> answering member printed Lord Prior of Brampton grouped question UIN HL4015 question first answered 20/12/2016 15:21:45 answering member 127 label Biography information for Lord Prior of Brampton attachment 1 file name Zhang abstract ASRM Oct 2016 (1).pdf title ZHANG ABSTRACT
tabling member	738 label Biography information for Lord Alton of Liverpool

657381

registered interest
date	12/12/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	IVF
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government, further to the Written Answers by Lord Prior of Brampton on 17 October (HL2340) and 5 December (HL3452), whether members of the Human Fertilisation and Embryology Authority (HFEA) expert panel approached John Zhang or were approached by him, and when any such contact was first made; and to what extent, if any, the recent recommendations of the HFEA expert panel were influenced by the John Zhang's unpublished data referred to in the journal <i>Nature</i> on 10 November.
tabling member printed	Lord Alton of Liverpool
uin	HL4015
answer	answer is ministerial correction date of answer 20/12/2016 answer text <p>The Human Fertilisation and Embryology Authority (HFEA) has advised that the Expert Panel has met on four occasions over the past four years. On each occasion a formal call for evidence was issued. With regard to the most recent report, the Panel received confidential correspondence on particular issues. Panel members were able to share private correspondence with the Secretariat that supports the Panel, where relevant. Where any evidence has influenced the reports it has been cited.</p><p>The HFEA has also advised that it approached John Zhang, following the publication of the abstract from the October 2016 American Society for Reproductive Medicine meeting, entitled “First live birth using human oocytes reconstituted by spindle nuclear transfer for mitochondrial DNA mutation causing Leigh syndrome”. A copy of the abstract is attached. The Panel also interviewed Prof. Zhang to further understand the methods used. The Panel’s report references the Zhang work.</p> answering member printed Lord Prior of Brampton grouped question UIN HL4014 question first answered 20/12/2016 15:21:45 answering member 127 label Biography information for Lord Prior of Brampton attachment 1 file name Zhang abstract ASRM Oct 2016 (1).pdf title ZHANG ABSTRACT
tabling member	738 label Biography information for Lord Alton of Liverpool

657397

registered interest
date	12/12/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pancreatic Cancer: Research
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government, in the light of the five-year survival rate for patients suffering from pancreatic cancer, what funding has been provided for research into pancreatic cancer since 2010.
tabling member printed	Lord Porter of Spalding
uin	HL4030
answer	answer is ministerial correction date of answer 21/12/2016 answer text <p>The Department’s National Institute for Health Research (NIHR) funds and supports research into all aspects of human health. Spend on research funded directly by NIHR is categorised by Health Research Classification System (HRCS) categories, including ‘cancer’. There are no HRCS health sub-categories, such as for pancreatic cancer.</p><p> </p><p>The NIHR invested £745 million in cancer research from 2010-11 to 2015-16 (see table below). This figure includes investment in the NIHR Liverpool Pancreatic Biomedical Research Unit, which carries out research into pancreatic cancer and other pancreatic diseases.</p><p> </p><table><tbody><tr><td><p>Year</p></td><td><p>Cancer research</p></td></tr><tr><td><p>2010-11</p></td><td><p>£100,901</p></td></tr><tr><td><p>2011-12</p></td><td><p>£104,104</p></td></tr><tr><td><p>2012-13</p></td><td><p>£133,239</p></td></tr><tr><td><p>2013-14</p></td><td><p>£129,893</p></td></tr><tr><td><p>2014-15</p></td><td><p>£134,715</p></td></tr><tr><td><p>2015-16</p></td><td><p>£142,433</p></td></tr><tr><td><p>Total</p></td><td><p>£745,285</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p>Medical Research Council (MRC) spend on research into pancreatic cancer since 2011-12 is provided below. No directly comparable figure is available for 2010-11.</p><p> </p><table><tbody><tr><td><p>Year</p></td><td><p>Pancreatic Cancer Research</p></td></tr><tr><td><p>2011-12</p></td><td><p>£0.37 million</p></td></tr><tr><td><p>2012-13</p></td><td><p>£1.11 million</p></td></tr><tr><td><p>2013-14</p></td><td><p>£1.66 million</p></td></tr><tr><td><p>2014-15</p></td><td><p>£2.22 million</p></td></tr><tr><td><p>2015-16</p></td><td><p>£2.66 million</p></td></tr></tbody></table><p> </p><p>To provide context, in 2015, the MRC’s overall expenditure on cancer research was £90.3 million (calendar year figure, source: National Cancer Research Institute). This figure includes a broad portfolio of site-specific and general underpinning cancer research, some of which will be relevant to research into pancreatic cancer, as it is often the case that research relevant to one site may also have implications for other forms of cancer.</p> answering member printed Lord Prior of Brampton question first answered 21/12/2016 13:53:42 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	4555 label Biography information for Lord Porter of Spalding

657402

registered interest
date	12/12/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hospital Beds
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what is the transfer of care rate for each local authority in England; and what assessment they have made of the reasons for any differences in the transfer of care rate between local authorities.
tabling member printed	Lord Wills
uin	HL4035
answer	answer is ministerial correction date of answer 21/12/2016 answer text <p>NHS England compiles and publishes monthly delayed transfers of care data. The data is available by each local authority and National Health Service trust, and includes the reason for the delay against a defined set of 10 categories. The data set is published in an online-only, interactive format.</p><p> </p><p>Delays have multiple causes and as a result there is variation between local authorities. A wide-ranging package of support is in place to help areas improve transfers out of hospital and reduce delays, including work as part of Accident and Emergency Improvement Plans to understand and address delays in hospital discharge and promote good practice.</p><p> </p><p>The NHS and local government have also developed new resources, including a high impact change model for reducing delayed transfers of care. In addition, the Emergency Care Improvement Programme provides tailored support to local systems to support rapid and sustained improvement in performance.</p> answering member printed Lord Prior of Brampton question first answered 21/12/2016 13:53:02 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	260 label Biography information for Lord Wills

657407

registered interest
date	12/12/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Social Services: Fees and Charges
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government whether they intend to bring into effect the provisions in the Care Act 2014 for capping individual liability for meeting the costs of adult social care; and if so, when.
tabling member printed	Lord Warner
uin	HL4040
answer	answer is ministerial correction date of answer 19/12/2016 answer text <p>The Government remains committed to introducing a cap on care costs and extension of means-tested support, which will be implemented from April 2020.</p> answering member printed Lord Prior of Brampton question first answered 19/12/2016 17:01:17 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	1732 label Biography information for Lord Warner

657408

registered interest
date	12/12/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Care Homes: Fees and Charges
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what is their policy regarding proprietors of nursing and residential care homes subsidising the care of publicly funded residents from payments by private payers; and what guidance they have issued on this to local authorities or care home proprietors.
tabling member printed	Lord Warner
uin	HL4041
answer	answer is ministerial correction date of answer 20/12/2016 answer text <p>Care and support is arranged on an open market where prices and fee rates are negotiated locally by commissioners for state-funded clients, whilst individuals and their families do so for those who self-fund. The Government has no say in these individual negotiations.</p><p> </p><p>There are many reasons why individuals who self-fund may pay more than local authorities, including premium accommodation and services, and discounts that may be available to authorities for bulk purchasing and lower transaction costs.</p><p> </p><p>The Care Act placed duties on councils to promote their overall local market of providers to ensure it remains sustainable as to deliver high-quality services for all local people. Prices and fee rates paid by commissioners to provider organisations must reflect these new duties.</p><p> </p><p>The Department published the Care and Support statutory guidance setting out how councils should meet these new duties when commissioning, including the consideration of the actual costs of care and support when negotiating fee levels. This guidance is an online-only resource, subject to updates.</p> answering member printed Lord Prior of Brampton question first answered 20/12/2016 12:50:05 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	1732 label Biography information for Lord Warner